<DOC>
	<DOCNO>NCT01431534</DOCNO>
	<brief_summary>This study find maximum tolerate dose ( MTD ) pharmacokinetic ( PK ) data ridaforolimus give participant age 6 17 year advance solid tumor . Study-related visit conclude August 2013 . Participants may continue treatment meet discontinuation criterion voluntarily withdraw .</brief_summary>
	<brief_title>A Study Ridaforolimus Pediatric Patients With Advanced Solid Tumors ( MK-8669-056 )</brief_title>
	<detailed_description />
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : Histologic cytologic diagnosis malignant solid tumor , include tumor central nervous system lymphoma , progress despite standard therapy effective standard therapy know . Patients receive standard therapy continue biopsyproven residual stable disease eligible Measurable nonmeasurable disease Must able swallow tablet Performance Status : Lansky Play Scale ≥70 child &lt; 10 year age ; Karnofsky score ≥70 child ≥10 &lt; 16 year ; Eastern Cooperative Oncology Group ( ECOG ) Status 02 patient age 16 old Adequate organ function For female reproductive potential , negative pregnancy test must document within 72 hour receive first dose study medication Participants reproductive potential must agree use ( partner use ) adequate contraception throughout study , start Visit 1 30 day last dose study drug Exclusion criterion : Currently receive investigational agent use investigational device Leukemia Participant previously receive ridaforolimus , rapamycin , rapamycin analog History allergic reaction attribute compound similar chemical biologic composition ridaforolimus Persistent acute toxicity previous therapy ≥Grade 2 ( exclude alopecia , neuropathy , hearing loss ) Uncontrolled intercurrent illness despite adequate therapy Pregnant breastfeeding Requirement concurrent treatment medication inducer inhibitor cytochrome P450 ( CYP3A ) Poorly control Type 1 2 diabetes</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>